Recent Posts on This Topic | See All >
[Source: TGen] - The Translational Genomics Research Institute (TGen) and Asuragen Inc. today announced a research agreement that could lead to ways of detecting cancer before it spreads.
TGen’s Dr. Glen Weiss, an Associate Investigator in TGen’s Cancer and Cell Biology Division, plans initially to work with Asuragen to search for new ways of screening patients for pancreatic cancer, one of the fastest moving and deadliest types of cancer.
The project will combine the microRNA expertise and diagnostic development experience of Asuragen with TGen’s strengths in basic and clinical research.
For more information: TGen-Asuragen partner to advance pancreatic cancer research
Now available: “Action and Impact," a 2014 report on the grant programs and activities of the Flinn Foundation in Arizona biosciences, civic leadership, arts and culture, and the Flinn Scholars program.